Towards an integrated systems-based modelling framework for drug transport and its effect on tumour cells

Journal of Biological Engineering

Volumn 8, Issue 1, 2014, Pages

  Liu, Cong ^a   Krishnan, J ^a   Xu, Xiao Y ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drug effect; Drug transport; in silico experimental platform; Intracellular signalling; Systems based modelling framework

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN;

APOPTOSIS; ARTICLE; BLOOD FLOW; BLOOD FLOW VELOCITY; BLOOD VESSEL; CELL DENSITY; DRUG CONCENTRATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PENETRATION; DRUG TRANSPORT; HYDRAULIC CONDUCTIVITY; INTERSTITIUM; INTRACELLULAR SIGNALING; MICHAELIS CONSTANT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUMOR CELL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; COMPUTER MODEL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG INTERACTION; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; SYSTEMS BIOLOGY;

EID: 84892419425     PISSN: None     EISSN: 17541611     Source Type: Journal    
DOI: 10.1186/1754-1611-8-3     Document Type: Article

References (50)

1. Venkatasubramanian R, Henson MA, Forbes NS. Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. J Theor Biol 2008, 253:98-117. 10.1016/j.jtbi.2008.02.016, 2517579, 18402980.
2. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592. 10.1038/nrc1893, 16862189.
3. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454. 10.1093/jnci/djm135, 17895480.
4. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990, 50:4478-4484.
5. Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 2006, 66:1033-1039. 10.1158/0008-5472.CAN-05-3077, 16424039.
6. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000, 60:2497-2503.
7. Kreeger PK, Lauffenburger DA. Cancer systems biology: a network modeling perspective. Carcinogenesis 2010, 31:2-8. 10.1093/carcin/bgp261, 2802670, 19861649.
8. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000, 256:42-49. 10.1006/excr.2000.4838, 10739650.
9. Kohn KW, Jackman J, Oconnor PM. Cell-cycle control and cancer-chemotherapy. J Cell Biochem 1994, 54:440-452. 10.1002/jcb.240540411, 8014193.
10. Martin GS. Cell signaling and cancer. Cancer Cell 2003, 4:167-174. 10.1016/S1535-6108(03)00216-2, 14522250.
11. Cloutier M, Wang E. Dynamic modeling and analysis of cancer cellular network motifs. Integr Biol 2011, 3:724-732.
12. Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, Clarke R. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer 2011, 11:523-532. 10.1038/nrc3081, 3294292, 21677677.
13. Liu C, Krishnan J, Stebbing J, Xu XY. Use of mathematical models to understand anticancer drug delivery and its effect on solid tumors. Pharmacogenomics 2011, 12:1337-1348. 10.2217/pgs.11.71, 21919608.
14. El-Kareh AW, Secomb TW. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2000, 2:325-338. 10.1038/sj.neo.7900096, 1550297, 11005567.
15. Kuh HJ, Jang SH, Wientjes MG, Au JL. Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther 2000, 293:761-770.
16. Chappell MJ, Evans ND, Errington RJ, Khan IA, Campbell L, Ali R, Godfrey KR, Smith PJ. A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan. Comput Methods Programs Biomed 2008, 89:169-178. 10.1016/j.cmpb.2007.11.002, 18082908.
17. Eikenberry S. A tumor cord model for doxorubicin delivery and dose optimization in solid tumors. Theor Biol Med Model 2009, 6:16. 10.1186/1742-4682-6-16, 2736154, 19664243.
18. Thurber GM, Weissleder R. A systems approach for tumor pharmacokinetics. PLoS One 2011, 6:e24696. 10.1371/journal.pone.0024696, 3173470, 21935441.
19. Goh Y-MF, Kong HL, Wang C-H. Simulation of the delivery of doxorubicin to hepatoma. Pharm Res 2001, 18:761-770. 10.1023/A:1011076110317, 11474779.
20. El-Kareh AW, Secomb TW. A mathematical model for cisplatin cellular pharmacodynamics. Neoplasia 2003, 5:161-169. 1502402, 12659689.
21. El-Kareh AW, Secomb TW. Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. Neoplasia 2005, 7:705-713. 10.1593/neo.05118, 1501422, 16026650.
22. El-Kareh AW, Labes RE, Secomb TW. Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs. AAPS J 2008, 10:15-34. 10.1208/s12248-007-9003-6, 2751448, 18446502.
23. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004, 64:1094-1101. 10.1158/0008-5472.CAN-03-2524, 14871843.
24. Kozusko F, Chen P, Grant SG, Day BW, Panetta JC. A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Math Biosci 2001, 170:1-16. 10.1016/S0025-5564(00)00065-1, 11259801.
25. Jackson TL. Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model. J Theor Biol 2003, 220:201-213. 10.1006/jtbi.2003.3156, 12468292.
26. Jang SH, Wientjes MG, Au JL. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 2001, 296:1035-1042.
27. Zheng JH, Chen CT, Au JL, Wientjes MG. Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci 2001, 3:E15. 10.1208/ps030318, 2779556, 11741266.
28. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989, 37:77-104. 10.1016/0026-2862(89)90074-5, 2646512.
29. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res 1990, 40:246-263. 10.1016/0026-2862(90)90023-K, 2250603.
30. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 1991, 41:5-23. 10.1016/0026-2862(91)90003-T, 2051954.
31. Teo CS, Hor Keong Tan W, Lee T, Wang C-H. Transient interstitial fluid flow in brain tumors: effect on drug delivery. Chem Eng Sci 2005, 60:4803-4821.
32. Netti PA, Roberge S, Boucher Y, Baxter LT, Jain RK. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 1996, 52:27-46. 10.1006/mvre.1996.0041, 8812751.
33. Pozrikidis C, Farrow DA. A model of fluid flow in solid tumors. Ann Biomed Eng 2003, 31:181-194.
34. Liu C, Krishnan J, Xu XY. A systems-based mathematical modelling framework for investigating the effect of drugs on solid tumours. Theor Biol Med Model 2011, 8:45. 10.1186/1742-4682-8-45, 3261817, 22152406.
35. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988, 48:2641-2658.
36. Baish JW, Gazit Y, Berk DA, Nozue M, Baxter LT, Jain RK. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res 1996, 51:327-346. 10.1006/mvre.1996.0031, 8992232.
37. Peters W, Teixeira M, Intaglietta M, Gross JF. Microcirculatory studies in rat mammary carcinoma. I. Transparent chamber method, development of microvasculature, and pressures in tumor vessels. J Natl Cancer Inst 1980, 65:631-642.
38. Seaton D, Krishnan J. Modular systems approach to understanding the interaction of adaptive and monostable and bistable threshold processes. IET Syst Biol 2011, 5:81-94. 10.1049/iet-syb.2009.0061, 21405196.
39. Albeck JG, Burke JM, Spencer SL, Lauffenburger DA, Sorger PK. Modeling a snap-action, variable-delay switch controlling extrinsic cell death. PLoS Biol 2008, 6:2831-2852. 2592357, 19053173.
40. Legewie S, Bluthgen N, Herzel H. Mathematical modeling identifies inhibitors of apoptosis as mediators of positive feedback and bistability. Plos Comput Biol 2006, 2:1061-1073.
41. Gu C, Zhang J, Chen Y, Lei J. A trigger model of apoptosis induced by tumor necrosis factor signaling. BMC Syst Biol 2011, 5(Suppl 1):S13.
42. Zhang T, Brazhnik P, Tyson J. Computational analysis of dynamical responses to the intrinsic pathway of programmed cell death. Biophys J 2009, 97:415-434. 10.1016/j.bpj.2009.04.053, 2711321, 19619456.
43. Eissing T, Conzelmann H, Gilles ED, Allgower F, Bullinger E, Scheurich P. Bistability analyses of a caspase activation model for receptor-induced apoptosis. J Biol Chem 2004, 279:36892-36897. 10.1074/jbc.M404893200, 15208304.
44. Bentele M, Lavrik I, Ulrich M, Stosser S, Heermann DW, Kalthoff H, Krammer PH, Eils R. Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol 2004, 166:839-851. 10.1083/jcb.200404158, 2172102, 15364960.
45. Bagci EZ, Vodovotz Y, Billiar TR, Ermentrout GB, Bahar I. Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J 2006, 90:1546-1559. 10.1529/biophysj.105.068122, 1367306, 16339882.
46. Krishnan J, Liu C. An investigation of signal transduction and irreversible decision making through monostable and bistable switches. Systems and Synthetic Biology: A Systematic Approach 2012, Springer Verlag, Kulkarni V, Stan G-B, Raman K, In press.
47. Edelstein-Keshet L. Mathematical Models in Biology 1988, SIAM, 3600 Market Street, Floor 6, Philadelphia, PA 19104: Society for Industrial and Applied Mathematics.
48. Eksborg S, Andersson M, Domellöf L, Lönroth U. A pharmacokinetic study of adriamycin and 4′epi-adriamycin after simultaneous intra-arterial liver administration. Med Oncol Tumor Pharmacother 1986, 3:105-110.
49. Robert J. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Canc Clin Oncol 1982, 18:739-745.
50. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987, 47:3039-3051.